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Purpose

Excessive fibrosis has been suggested to result from persistence of fibroblasts in injured tissue due to
impaired apoptosis, but signaling pathways are not fully defined.

Methods

 uppression of apoptotic cell death following transforming growth factor-β1 (TGF-β1) exposure was
S
studied using the culture of NIH/3T3 mouse embryonic fibroblasts. Caspase-3 activity, propidium iodide
staining and annexin V binding induced by Fas-ligand (FasL) in NIH/3T3 fibroblasts in the absence
and presence of TGF-β1 was determined, and relative contribution of signaling through Smad2/3
and noncanonical Erk1/2 and Akt pathways was dissected by assessing phosphorylation status of
these kinases and caspase activity in the absence and presence of specific inhibitors (SB431542,
PD0325901 and LY294002), respectively.

Results

 GF-β1 treatment suppressed FasL-mediated fibroblasts apoptosis with a greater than threefold
T
reduction of caspase-3 activity (from 894 ± 186 to 195 ± 56 nmol AFC/min/106 cells at 250 ng/mL of
FasL) and reductions in cleaved caspase-8 and caspase-3 by 3.2-fold and 4.3-fold, respectively. The
reduction in caspase activation was accompanied by a decrease in annexin V-positive cells by ~80%.
TGF-β1 treatment phosphorylated Smad2/3, Erk1/2 and Akt, which were reduced by their selective
inhibitors. Inhibition of Smad2/3 and Erk1/2 alone partially reduced the protective effect of TGF-β1
on caspase-3 activation, whereas inhibition of the Akt pathway had no significant effect. Concomitant
inhibition of Smad2/3 and Erk1/2 completely reversed the protection by TGF-β1.

Conclusions

 GF-β1-mediated suppression of apoptosis in fibroblasts involves both Smad2/3 and Erk1/2 pathways,
T
but not the Akt pathway. A combined approach inhibiting Smad2/3 and Erk1/2 pathways can completely
reverse the protective effect of TGF-β1 on apoptosis. These findings are proof of concept to help
define strategies to reduce progression of fibrosis and resultant morbidities associated with conditions
causing excessive fibrosis, including but not limited to keloid formation, transplant fibrosis and agingassociated fibrosis of the heart. (J Patient Cent Res Rev. 2016;3:187-198.)
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Fibroblasts are the major cells involved in extracellular
matrix remodeling and repair of injured tissue.1-12
Following extracellular matrix deposition, activated
fibroblasts undergo programmed cell death or
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dedifferentiate to quiescent phenotype, keeping the
fibrotic process in check. Impairment of programmed
cell death can result in persistence of these cells, which
may contribute to progressive fibrosis and mechanical
and electrical dysfunction in organs such as the heart,
thereby predisposing a person to pathology that
increases morbidity and mortality.12-14
Apoptotic cell death and cell regulatory signaling
cascades, as well as interactions between participating
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proteins and cascades, are extremely complex.15
Programmed cell death is based on sequential
activation of intracellular enzymes called caspases
(stemming from cysteine-dependent, aspartatedirected proteases), a family of protease enzymes
that play essential roles in initiation and progression
of programmed cell death.16 Activation of crucial
executional enzymes of this pathway, namely
caspase-3, have been established as the key and
executional protease commonly involved in all known
mechanisms of extrinsic, intrinsic or mixed type of
apoptotic cell death.17 It is important to understand
mechanisms underlying excessive fibrosis and identify
targets to prevent such complications to reduce
morbidity and mortality associated with the growing
epidemic of aging-associated diseases.2,4,12,14,18-23
Transforming growth factor-β1 (TGF-β1), a profibrotic
cytokine, has a variable effect on cell survival and
proliferation depending on the cell type and clinical
condition, with both proapoptotic and antiapoptotic
effects previously described.24 The effect of TGF-β1
receptor activation on differentiation and maturation
of fibroblasts is mediated through two intracellular
signaling pathways: 1) canonical, Smad-dependent, and
2) noncanonical, Erk1/2-dependent. Smad-dependent
signaling is specifically activated with TGF-β1, a
cytokine increased during inflammation, heart failure
and other diseased states and which plays a crucial role
in translation of cytoplasmic signals into the nucleus to
induce activation of profibrotic transcription factors.25
In addition, a noncanonical signaling pathway known
as the Ras-Raf-MEK-Erk1/2 pathway, which involves
a chain of intracellular proteins, transduces TGF-β1
receptor activation on the surface of the cell to the DNA
in the nucleus, thereby promoting cell proliferation,
differentiation and migration.26
Although both signaling pathways downstream of
TGF-β1 receptors are important in promoting fibrosis
by proliferation and persistence of fibroblasts through
inhibition of programmed cell death,27,28 their relative
contribution to the antiapoptotic effect of TGF-β1 is not
well defined. It also is not clear whether inhibiting one of
these downstream pathways alone is sufficient to reverse
TGF-β1’s antiapoptotic effect. Therefore, we sought
to determine the relative role of Smad-dependent and
Smad-independent (i.e. Ras-Raf-MEK-Erk1/2 and Akt)
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intracellular signaling pathways in TGF-β1-mediated
suppression of Fas ligand (FasL)-mediated apoptosis in
an NIH/3T3 mouse embryo fibroblast cell line.
Identifying the relative contribution of canonical and
noncanonical intracellular signaling in the mediation
of the antiapoptotic effect of TGF-β1 in fibroblasts
may help design novel strategies to reduce progression
of fibrosis and the resultant morbidity associated with
conditions promoting this excessive tissue scarring.

METHODS

Materials
NIH/3T3 Mouse Embryonic Fibroblasts: NIH/3T3 cells
(ATCC® CRL-1658™) were purchased from American
Type Culture Collection (ATCC, Manassas, VA).
Authentication of cells during propagation and long-term
storage was verified using bright-field microscopy per
ATCC recommendations (https://www.atcc.org/~/media/
PDFs/Technical%20Bulletins/tb08.ashx). Comparison of
cellular morphology of intact, naive and TGF-β1-treated
cells was used as read-out of authenticity of NIH/3T3
cells susceptible to TGF-β1-dependent maturation and
differentiation followed by morphological changes from
a naive triangular morphology with few processes in the
absence of TGF-β1 to mature differentiated cells that
formed clearly identifiable “stripes” of large cells with
multiple processes in the presence of TGF-β1. These
morphological changes were acquired by cells after
at least 48 hours exposure to TGF-β1 and retained by
cell line at 60%–80% plating density (confluence). For
the duration of this study, morphological checking of
NIH/3T3 responsiveness to TGF-β1 for each new passage
and batch of cells was performed.
Chemicals: All chemicals were purchased from
Sigma-Aldrich Corp. (St. Louis, MO) unless specified.
Recombinant TGF-β1 was obtained from PeproTech
(Rocky Hill, NJ) and recombinant caspase-3 from
Cell Signaling Technology Inc. (Danvers, MA). The
caspase-3 substrate Ac(N-acetyl)-DEVD-7-amino4-trifluoromethylcoumarin (Ac-DEVD-AFC) and
AFC (for calibration) were obtained from Santa
Cruz Biotechnology Inc. (Dallas, TX). FasL and
antibodies against phospho-Smad2/3, Smad2/3,
tubulin, phospho-Erk1/2, Erk1/2, phospho-Akt, Akt,
procaspase-3, caspase-3, glyceraldehyde phosphate
dehydrogenase (GAPDH) and secondary goat anti-
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rabbit immunoglobulin G (IgG) were purchased from
Cell Signaling Technology. Annexin V/Alexa Fluor®
488 dye mixture was obtained from Thermo Fisher
Scientific Inc. (Waltham, MA). SB431542 was used as
a specific inhibitor of Smad2; PD0325901, an MEK
inhibitor, was used to inhibit Erk phosphorylation; and
LY294002 was used as an inhibitor of the Akt pathway.
Cell Culture
NIH/3T3 fibroblasts were cultured in high-glucose
DMEM media (ATCC) containing 10% bovine calf
serum and 1% penicillin/streptomycin (both additives
from Thermo Fisher Scientific) at 37°C in a humidified
chamber supplemented with 5% carbon dioxide as
previously described.11 Cells of passage 3 were used
after propagating from passage 0 obtained from vendor.
TGF-β1 Treatment
Cultured NIH/3T3 fibroblasts were treated with
recombinant TGF-β1 as previously described.2,9,14,29-31
Briefly, cells were plated at the indicated density
using complete cell culture media (10% fetal bovine
serum) and incubated overnight at 95% air/5% carbon
dioxide to allow attachment. Subsequently, cells were
transferred into an incubation media with low serum
(2.5%) for sensitization toward exogenous growth
factors.11,32 Following 24 hours of sensitization,
NIH/3T3 fibroblasts were further incubated for the
indicated time in low-serum media supplemented with
either 5 ng/mL of TGF-β1 (experimental group) or an
appropriate volume of incubation media as a vehicle
(control group). The workflow and setup used in these
experiments are shown in Figure 1.

Measurement of Caspase-3
For caspase-3 activity assays, NIH/3T3 fibroblasts
were grown in 96-well plates coated with rat tail
collagen I (Sigma-Aldrich) at a density of 50,000 cells/
cm2. After 24 hours, media was replaced with 200 µl
of low-serum incubation media (2.5% fetal bovine
serum) and cells incubated for another 24 hours. After
24 hours, incubation media was replaced with 90 µl of
low-serum media containing FasL (0.25–1 µg/ml) or
vehicle. Following 6 hours of incubation, 90 µl of lysis
buffer (HEPES 50 mM, CHAPS 10 mM, dithiothreitol
20 mM, pH 7.4) was added and the plate incubated at
room temperature for 5 minutes. Cell lysates were then
mixed with 100 µl of the caspase-3 reaction mixture
containing HEPES 50 mM, sodium chloride 200 mM,
ethylenediaminetetraacetic acid 2 mM, CHAPS 3 mM,
dithiothreitol 20 mM and 10% sucrose and supplemented
with highly specific caspase-3 substrate Ac-DEVD-AFC
(50 µM). Caspase-3 cleaves the tetrapeptide between D
and AFC, thus releasing the fluorogenic AFC, which was
measured using Infinite® 200 PRO reader (Tecan Group
Ltd., Männedorf, Switzerland) at 400 nM excitation
and 505 nM emission. Commercial AFC was used for
calibration of the fluorescence, and caspase-3 activity
was expressed as nmol of coumarin/min/106 cells.
Annexin V and Propidium Iodide Binding Assays
Fibroblasts, grown on collagen-coated glass surfaces
of MatTek dishes, were exposed to TGF-β1 and treated
with FasL. Following incubation with TGF-β1 and
FasL, cells were washed with annexin binding buffer
and then stained using a 1:10 mixture of annexin V
and Alexa Fluor 488 dye (a fluorescent marker of

Figure 1. Diagram of experimental workflow. Cells were plated in complete incubation media (10% FBS) and
incubated overnight (16–18 hours) to let fibroblasts attach. Cell sensitization was achieved by transferring the cells
into low-serum media (2.5% FBS) for 24 hours. Following the sensitization period, cells were treated with TGF-β1 for
3 hours and exposed to FasL for another 6 hours. At that point cells were used for monitoring indicated parameters.
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phosphatidylserine-enriched zones on the outer surface
of the plasma membrane), 1 µg/ml of Hoechst 33342
(a cell-permeant fluorescent nuclear dye for quantification
of the cell number) and 10 µg/ml propidium iodide
(a plasma membrane-impermeable red nuclear
fluorescing dye). Fluorescent images of NIH/3T3
fibroblasts were acquired in green (annexin V), blue
(cell nuclei) and red (propidium iodide) channels using
40× magnification, 0.5% power of excitation lines,
and gain set at 850 for all three channels of the laserscanning confocal microscope (FV1200, Olympus
Corp., Waltham, MA). Confocal images of all three
fluorophores were analyzed using ImageJ software. The
total number of cells taken into analysis was determined
from the total number of cell nuclei stained with Hoechst
33342 (λex/em = 350/461 nm, blue fluorescence), the
number of apoptotic cells was determined by the number
of green cells labeled with annexin V/Alexa Fluor 488
(λex/em = 488/499 nm), and the number of necrotic cells
was derived from the number of propidium iodidepositive cells (λex/em = 535/617 nm, red fluorescence).

antibodies (Cell Signaling Technology) were used as
secondary antibodies. The bands on the membrane
were visualized using Clarity™ ECL Western Blotting
Substrate (Bio-RAD, Hercules, CA), and images were
taken using Amersham™ Imager 600 (GE Healthcare
Life Sciences, Pittsburgh, PA). Western blot images
were analyzed by ImageJ. Densities of bands of
interest were normalized to the density of respective
bands for GAPDH. Normalization to tubulin was used
when molecular weight overlap was present between
proteins of interest and GAPDH.

Western Blotting
Activation of intracellular signaling molecules
(Smad2/3, stress kinases Erk1/2, Akt), their
phosphorylated forms and the active caspase-3 level
in cells were assessed using western blot. Cultured
fibroblasts were treated as described and solubilized
using radioimmunoprecipitation assay (RIPA) buffer
supplemented with a protease/phosphatase inhibitor
cocktail per manufacturer’s instructions (SigmaAldrich). Protein concentration of obtained cell
lysates was determined using Pierce™ BCA Protein
Assay Kit (Thermo Fisher Scientific). Protein samples
were mixed with NuPAGE® LDS Sample Buffer and
NuPAGE Reducing Agent, heated at 70°C for 15
minutes, and the total of 15 µg of protein was loaded
in each well of 4%–12% Bis-Tris gel (Thermo Fisher
Scientific). The samples were separated at 110 V for
~2 hours using MOPS/SDS Running Buffer (Thermo
Fisher Scientific). Separated proteins were then
transferred to nitrocellulose membranes using the
iBlot® system (Thermo Fisher Scientific).

RESULTS

Poteins of interest were detected using primary rabbit
IgG antibodies to Smad2, Smad3, Erk1, Erk2, Akt,
caspase-3, caspase-8, caspase-9, tubulin and GAPDH
(Cell Signaling Technology), and goat anti-rabbit IgG
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Statistical Analysis
Because no human or animal subjects were involved in
this study, institutional review board approval was not
required. Each experiment was performed in triplicate,
with “n” representing the number of experiments.
Data were expressed as means ± standard error of
mean. Comparison between groups for each assay was
performed using Student’s t-test analysis, and P<0.05
was considered to be statistically significant.
TGF-β1 Treatment Desensitizes NIH/3T3
Fibroblasts to FasL-Induced Apoptotic Cell
Death
To assess the effect of TGF-β1 on survival against
apoptosis induced by activators of extrinsic pathways,
fibroblasts were incubated in the absence and presence
of TGF-β1 for 3 hours and treated with increasing doses
of FasL (250–1,000 ng/ml). FasL induced activation of
caspase-3 in a dose-dependent manner, with caspase-3
activity increasing from 232 ± 52 nmol AFC/min/106
cells at baseline to 895 ± 186 nmol AFC/min/106 cells
at 250 ng/ml, 1618 ± 167 nmol AFC/min/106 cells at
500 ng/ml and 2,371 ± 249 AFC/min/106 cells at 1,000
ng/ml of FasL (n=3, P<0.02) (Figure 2A). TGF-β1
pretreatment (5 ng/mL) reduced caspase-3 activation
at all doses of FasL by more than threefold (from 895
± 186 to 195 ± 56 nmol AFC/min/106 cells at 250 ng/
ml of FasL, from 1618 ± 167 to 365 ± 65 nmol AFC/
min/106 cells at 500 ng/ml of FasL and from 2,371 ±
249 to 696 ± 101 nmol AFC/min/106 cells at 1,000 ng/
ml of FasL (n=3, P<0.03) (Figure 2A). The dose of
250 ng/ml of FasL was used for further experiments
(Figure 2B). Thus, FasL-induced caspase-3 activity
was reduced by pretreatment of fibroblasts with
TGF-β1.
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Figure 2. TGF-β1 treatment desensitizes NIH/3T3 fibroblasts toward FasL-induced apoptotic cell death.

A: Dose-dependent effect of FasL on activation of caspase-3 in NIH/3T3 cells in the absence (open circles)
and presence (closed circles) of TGF-β1 exposure (5 ng/ml for 3 hours; n=3, P<0.02 compared with non-TGFβ1-treated cells). B: A quantitative representation of caspase-3 activation in NIH/3T3 fibroblasts treated with a
single dose of FasL (250 ng/ml) in the absence (open bar) and presence (closed bar) of TGF-β1 (n=3, P<0.03
compared with non-TGF-β1-treated cells).

TGF-β1-Mediated Reduction in FasL-Induced
Caspase-3 Activation Is Associated With
Reduced Apoptotic Cell Death
Treatment of NIH/3T3 fibroblasts with FasL (250 ng/
ml) resulted in increased cell death as demonstrated by
increased staining of nuclei with propidium iodide and
increased annexin V binding (Figure 3A), indicative
of apoptosis. At baseline in the absence of FasL, the
number of propidium iodide- and annexin V-positive
cells was negligible. FasL treatment resulted in 76% ±
17% of cells staining with annexin V and 54% ± 22%
of cells staining with propidium iodide. Pretreatment
of cells with TGF-β1 reduced annexin V and
propidium iodide staining (Figure 3A). On average, the
percentage of annexin V-positive cells decreased from
76% ± 17% in cells not exposed to TGF-β1 to 15% ±
3% in cells exposed to TGF-β1 (5 ng/ml for 3 hours),
demonstrating ~80% decrease of cell death by TGF-β1
(n=5, P<0.04) (Figure 3B). Similarly, the percentage
of propidium iodide-positive cells decreased from 54%
± 22% in the absence of TGF-β1 to 5% ± 4% in the
presence of TGF-β1 (n=5, P<0.05) (Figure 3C). Thus,
TGF-β1 desensitized NIH/3T3 fibroblasts toward
FasL-mediated cell death.
Original Research

TGF-β1 Prevents Activation of Caspase-3 and
Cell Death by FasL Through Suppression of
Caspase-8 Activation
To confirm that TGF-β1 reduces FasL-mediated cell death
through the extrinsic pathway of apoptosis that involves
activation of caspase-8, the cleavage of caspase-3 and
caspase-8 was assessed. Baseline expression levels
of normalized cleaved caspase-3 and caspase-8 were
negligible and not different in cells treated with or
without TGF-β1 (Figure 4). FasL treatment resulted in
an approximately 23-fold increase of cleaved caspase-3
from baseline densitometric ratio (caspase-3 to tubulin)
of 0.006 ± 0.001 to 0.120 ± 0.018 in fibroblasts (Figure
4A). Pretreatment of cells with TGF-β1 before FasL
exposure resulted in an approximately fourfold decrease
in cleavage of caspase-3 in fibroblasts (densitometric ratio
of caspase-3 to tubulin from 0.120 ± 0.018 in untreated
cells to 0.030 ± 0.005 in TGF-β1-treated cells; n=3,
P<0.01). Similar results with an approximately threefold
reduction of normalized cleaved caspase-8 levels were
observed when FasL-treated cells were pretreated with
TGF-β1 (densitometric ratio of caspase-8 to GAPDH
from 0.34 ± 0.05 in untreated cells to 0.11 ± 0.02 in treated
cells; n=3, P<0.01) (Figure 4B). There was no difference
www.aurora.org/jpcrr
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Figure 3. TGF-β1 treatment suppresses early signs of FasL-induced apoptotic cell death. A: Representative

fluorescent confocal images of NIH/3T3 fibroblasts treated with FasL (250 µg/ml for 6 hours) in the absence
(no TGF-β1) and presence (TGF-β1) of TGF-β1. Cells were stained with 1:10 dilution of annexin V/Alexa
Fluor® 488 (green), 1 µg/ml of Hoechst 33342 (blue) and 50 µg/ml of propidium iodide (red). B: Bar graph of the
percentage of annexin V/Alexa Fluor 488-positive cells in the population of NIH/3T3 fibroblasts treated with FasL
in the absence (no TGF-β1) and presence (TGF-β1) of TGF-β1 (n=5, P<0.04). A total of 250 cells were quantified
for each condition. C: Bar graph of the percentage of propidium iodide-positive cells in the population of NIH/3T3
cells treated with FasL in the absence (no TGF-β1) and presence (TGF-β1) of TGF-β1 (n=5, P<0.05). A total of
250 cells were quantified for each condition.

in procaspase-3 and procaspase-8 expression at baseline
with FasL treatment or FasL combined with TGF-β1
treatment. Thus, pretreatment of NIH/3T3 fibroblasts
with TGF-β1 (5 ng/ml for 3 hours) before induction of
apoptotic cell death with FasL (250 ng/ml for 6 hours)
decreased caspase-3 activation through suppression of
caspase-8 cleavage.
TGF-β1 Treatment of NIH/3T3 Fibroblasts
Activates Both Canonical and Noncanonical
Intracellular Signaling Pathways
To further define the participation of canonical and
noncanonical TGF-β1 receptor-activated pathways,
we determined the phosphorylation of Smad2/3,
Erk1/2 and Akt in the presence and absence of specific
inhibitors in fibroblasts (Figure 5). TGF-β1 induced
a 7.5-fold increase in phosphorylation of Smad2
(densimetric ratio of phospho-Smad2 to GAPDH
from 0.04 ± 0.01 at baseline level to 0.30 ± 0.04 with
TGF-β1 treatment), a twofold increase in Erk1/2
(densimetric ratio of phospho-Erk 1/2 to GAPDH from
0.03 ± 0.004 at baseline to 0.07 ± 0.01 with TGF-β1
treatment) and a 12-fold increase in Akt (densimetric
ratio of phospho-AktErk to tubulin from 0.02 ± 0.01
at the baseline level to 0.25 ± 0.03 with TGF-β1
treatment). Increased phosphorylation was inhibited
by specific inhibitors of Smad2 (SB431542), Erk1/2
192 JPCRR • Volume 3, Issue 4 • Fall 2016

(PD0325901) and Akt (LY294002) pathways. Smad3
did not demonstrate substantial phosphorylation
following TGF-β1 exposure (data not shown). TGF-β1dependent activation of Smad2 was largely prevented
by SB431542 (10 µM). SB431542 decreased the
expression of phosphorylated Smad2 from 0.30 ± 0.04
to 0.08 ± 0.03 (densimetric ratio of phospho-Smad2
to GAPDH) in TGF-β1-treated fibroblasts (n=3,
P<0.02) (Figure 5A). Similarly, PD0325901 (200
nM) decreased the expression of TGF-β1-mediated
phosphorylated Erk1/2 from 0.07 ± 0.01 to 0.01 ± 0.01
(densimetric ratio of phospho-Erk 1/2 to GAPDH)
(n=3, P<0.03), and LY294002 (5 µM) suppressed the
ratio of phospho-Akt/tubulin from 0.25 ± 0.03 to 0.05
± 0.02 (n=3, P<0.02) in TGF-β1-treated fibroblasts
(Figure 5B, 5C).
TGF-β1-Dependent Suppression of FasLInduced Apoptosis Is Reversed by Inhibiting
Smad2/3 and Erk1/2 Pathways, but Not Akt
To elucidate the relative contributions of Smad-dependent
and Smad-independent TGF-β1-mediated intracellular
signaling pathways in protection against FasL-induced
apoptosis, the effect of specific inhibitors on FasLmediated activation of caspase-3 –– the executioner
of apoptotic cell death –– was assessed. After 30
minutes of treatment with specific inhibitors, cells were
Original Research
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Figure 4. TGF-β1 treatment suppresses FasL-induced processing of procaspase-8 and procaspase-3 in
NIH/3T3 cells. A: Western blot analysis of normalized caspase-3 (top) and procaspase-3 (bottom) levels in
FasL-treated NIH/3T3 fibroblasts (250 ng/ml for 6 hours) in the presence and absence of TGF-β1 (5 ng/ml) (n=3,
P<0.01). B: Western blot analysis of normalized caspase-8 (top) and procaspase-8 (bottom) levels in FasLtreated NIH/3T3 fibroblasts (250 ng/ml for 6 hours) in the presence and absence of TGF-β1 (5 ng/ml) (n=3,
P<0.01) compared to FasL-treated cells without TGF-β1 treatment. CNT, carbon nanotube; NS, no significance.

exposed to TGF-β1 and then treated with FasL to initiate
apoptotic cell death. In the absence of added inhibitors,
TGF-β1 suppressed caspase-3 activity by fourfold (n=4,
P<0.02) (Figure 6). This protective effect was reversed
by pretreatment with SB431542, which restored the
sensitivity of NIH/3T3 cell to FasL, resulting in caspase-3
activity increasing from 119 ± 35 nmol AFC/min/106
cells to 490 ± 88 nmol AFC/min/106 cells (n=4, P<0.04).
Similarly, caspase-3 activity increased from 119 ± 35
nmol AFC/min/106 cells to 352 ± 63 nmol AFC/min/106
cells in the presence of PD0325901 (n=4, P<0.05). In
contrast, LY294002 had no significant effect on TGFβ1-mediated protection (135 ± 26 nmol AFC/min/106
cells vs 119 ± 35 nmol AFC/min/106 cells; n=4, P=0.51).
Since PD0325901 and SB431542 when used alone
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partially restored the sensitivity of cells to FasL-induced
apoptosis that had been suppressed by TGF-β1, SB431542
and PD0325901 were used concomitantly to assess the
combinatory effect of inhibition of these two downstream
pathways. Co-treatment with the two inhibitors in the
presence of TGF-β1 completely restored the sensitivity
of FasL-induced caspase-3 activity to 846 ± 123 nmol
AFC/min/106 cells, similar to the levels in cells untreated
by TGF-β1 (n=4, P<0.01) (Figure 6). Thus, TGF-β1
exposure reversibly suppressed FasL-induced activation
of executioner caspase-3 through both canonical (Smaddependent) and noncanonical (Smad-independent
Erk1/2) intracellular signaling pathways. The protective
effect of TGF-β1 on FasL-induced apoptosis was not
affected by the Akt pathway.
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Figure 5. TGF-β1-induced activation of Smad2, Erk1/2 and Akt pathways was blocked by specific inhibitors

of TGF-β1 signaling pathway proteins in NIH/3T3 fibroblasts. Top sections: Western blots of Smad2 activation
in cells treated for 3 hours with TGF-β1 (5 ng/ml) only, or TGF-β1 plus SB431542 (10 µM) (A). Western blots
of Erk1 and Erk2 activation in cells treated for 3 hours with TGF-β1 only, or TGF-β1 plus PD031542 (200 nM)
in cells treated with FasL in the presence and absence of TGF- β1 (B). Western blots of Akt activation in cells
treated for 3 hours with TGF-β1 only, or TGF-β1 plus LY294004 (10 µM) (C). Bottom sections: Bar graphs
of the densities of normalized bands –– open bars indicate untreated cells, closed bars indicate cells exposed
to TGF-β1, and hatched bars indicate cells exposed to TGF-β1 in the presence of inhibitors (n=3 for each
condition). *P<0.02 compared to cells treated without TGF-β1; **P<0.03 compared to cells treated with TGF-β1.

DISCUSSION

The main finding of our study is that TGF-β1 has a
protective effect against FasL-mediated activation of
apoptosis as shown by suppressed caspase-3 activity,
reduced annexin V and propidium iodide staining and
decreased cleaved caspase-3 and caspase-8 levels
in NIH/3T3 fibroblasts. This protective effect was
mediated through both Smad-dependent and Smadindependent Erk1/2 pathways that individually
provided partial protection against FasL-mediated
caspase activation. Specific inhibition of Smad2/3 or
Erk1/2 phosphorylation alone only partially reversed
TGF-β1-mediated protection and concomitant
inhibition of both the pathways completely reversed
its protective effect. Although activated by TGF-β1,
the PI3K-Akt pathway was not involved in the
protective effect of TGF-β1 against FasL-mediated
apoptotic cell death. These findings indicate that
inhibition of both Smad2/3 and Erk1/2 pathways
is required to completely block the protective
effect of TGF-β1 receptor activation, which could
be clinically relevant for conditions of progressive
fibrosis in which persistence of myofibroblasts is
detrimental.
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Figure 6. TGF-β1-dependent suppression of

FasL-induced apoptosis is reversed by inhibition
of intracellular signaling pathways. FasL-induced
activation of caspase-3 in naive and TGF-β1exposed NIH/3T3 cells in the absence (open bars)
and presence (closed bars) of specific inhibitors
of phosphorylation of Smad2/3 (SB431542, SB),
Erk1/2 (PD0325901, PD) and Akt (LY294002, LY)
and combination of Smad2/3 and Erk1/2 inhibition
(SB+PD) (n=4, aP<0.02, bP<0.04, cP<0.01).
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The role of receptor-mediated TGF-β1 signaling in the
regulation of cell growth, proliferation, differentiation
and programmed cell death has been well documented
in various cell types.1,2,11,13,18,22,23 There is also increasing
evidence that signaling pathways downstream of
TGF-β1 receptors –– both canonical Smad-dependent
and noncanonical Smad-independent –– are involved in
mediating the effects of TGF-β1, including its antiapoptotic
effect.9,21,33-40 Our findings in NIH/3T3 fibroblasts indicate
that inhibition of a single pathway only partially reverses
the antiapoptotic effect of TGF-β1, suggesting that both
Smad-dependent and Erk1/2 pathways complement each
other in suppression of apoptosis. The underlying basis
for that is not completely understood and requires further
investigation. Phosphorylation of Smad2/3 results in
nuclear translocation of the Smad complex that regulates
transcription of genes that ultimately translate into
antiapoptotic effect.41 On the other hand, Erk kinases have
a direct effect on preventing activation of caspase-8 and
caspase-3.42 Thus, these two pathways complement each
other to prevent program cell death mediated by FasL.
The role of Erk pathways in TGF-β1-mediated
suppression of apoptosis has been studied in
macrophages, A-459 cells, NIH/3T3 and rat cardiac
fibroblasts using serum deprivation, ceramide exposure
and ischemia-reperfusion.38,40,43,44 Our findings extend
these observations to FasL, a direct ligand for death
receptor-induced apoptosis in NIH/3T3 fibroblasts.
The role of Erk pathways in apoptosis has been
previously demonstrated using NIH/3T3 cells
overexpressing Bad, which resulted in inactivation
of Erk pathways and reduced phosphorylated Erk
compared to cells without Bad transfection that
translated into enhanced sensitivity to ceramideand
serum
deprivation-mediated
apoptosis.45
Furthermore, increased phosphorylation of Erk1/2
by TGF-β1 correlated with the latter’s protective
effect against FasL.38 Pharmacologic inhibition of
Erk1/2 pathway by PD98059 also was shown to
reduce apoptosis mediated by serum deprivation and
ceramide production.38 We confirmed this finding with
a much more potent and highly sensitive inhibitor
of MEK kinase, PD0325901.46 Even at the highest
concentration used in our study, only partial reversal
(42%) of TGF-β1-mediated suppression of apoptosis
was observed, indicating that additional pathways are
responsible for TGF-β1-mediated protection.
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Besides Erk1/2 phosphorylation, TGF-β1 also
caused phosphorylation of Akt and Smad2/3, which
could be prevented by specific inhibitors. Smad2/3
phosphorylation induced by TGF-β1 was suppressed
by SB431542, a selective inhibitor of the TGF-β
receptor kinase (TRK).47 TRK inhibition results in
decreased Smad2/3 phosphorylation, thus preventing
downstream signaling and translocation of the
Smad complex to the nucleus. Pretreatment with
SB431542 partially reversed the protective effect
of TGF-β1 against FasL-mediated apoptosis (64%)
as demonstrated by partial restoration of caspase-3
activity as compared to cells untreated by TGF-β1.
Concomitant inhibition of both Smad2/3 and Erk1/2 by
SB431542 and PD0325901 pretreatment of NIH/3T3
fibroblasts prevented the protective effect of TGF-β1
against FasL-mediated activation of executioner
caspase-3 and apoptosis (Figure 6). Conversely,
inhibition of the Akt pathway by LY294002, an
effective inhibitor of Akt phosphorylation induced by
TGF-β1, had no impact on protective effect of TGF-β1
against FasL-mediated caspase-3 activation, indicating
this pathway is not critical for protection against
activators of Fas-associated protein with death domain
(FADD)-mediated cell death. Our data indicate that
the main effectors of TGF-β1-mediated suppression
of apoptosis in NIH/3T3 cells are the Smad2/3 and
Erk1/2 pathways, while the Akt pathway plays a
minimal, if any, role in TGF-β1-mediated suppression
of FasL-induced apoptosis in NIH/3T3 fibroblasts, as
illustrated in Figure 7.
Study Limitations
The current study was performed using an NIH/3T3
mouse embryonic fibroblast cell line as a proof-ofconcept study to demonstrate that TGF-β1-mediated
desensitization of fibroblast apoptosis results from
activation of intracellular signaling pathways that can
be targeted to reduce persistence of fibroblasts that
contribute to fibrosis progression. This needs to be
confirmed in fibroblasts derived from patient samples
to help define the utility of such an approach to reduce
progression of fibrosis and resultant morbidities
associated with conditions causing excessive fibrosis,
including but not limited to keloid formation,
transplant fibrosis and aging-associated fibrosis of
the heart.
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Figure 7. Schematic of TGF-β1 receptor-mediated intracellular signaling pathways protecting against Fas-

associated protein with death domain (FADD)-mediated caspase activation. Activation of FADD by binding of
its ligand (FasL) through binding to death receptor activates caspase-8, which in turn activates executional
caspase-3 and induces apoptotic cell death (blue lines). TGF-β1 binding to its receptor activates downstream
canonical and noncanonical signaling pathways. Phosphorylation of Smad2/3 results in formation of Smad
complex (Smad2/3/4), which translocates to the nucleus and binds to Smad response elements to activate gene
transcription, ultimately resulting in suppression of apoptosis. SB431542 inhibits TGF-β1 receptor kinase and
prevents Smad2/3 phosphorylation by TGF-β1 (purple line). TGF-β1 activates Ras protein with subsequent
phosphorylation of Erk1/2. Activation of Erk1/2 inhibits caspase-3 and caspase-8 activation. PD0325901
selectively inhibits MEK kinase, thus preventing Erk1/2 phosphorylation (light blue line). TGF-β1 signaling
activates phosphatidylinositol-3-kinases (PI3K), resulting in phosphorylation of Akt; however, this pathway
has no or minimal effect on protection against FasL-mediated apoptosis. LY294002 selectively inhibits Akt
phosphorylation by inhibiting PI3K. Red lines indicate inhibition of caspases and broken lines indicate minimum
involvement in TGF-β1-mediated protection in NIH/3T3 fibroblasts.

CONCLUSIONS

Although the current study does not dissect the
intimate details of TGF-β1-mediated protection
against FasL-induced apoptotic cell death, it provides
strong evidence of involvement of both the Smad2/3
and Erk1/2 pathways, as well as noninvolvement
of Akt, in this protective effect against extrinsic
apoptosis in NIH/3T3 fibroblasts. Because fibroblasts
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are the major cell types involved in extracellular
matrix remodeling and their persistence can lead to
excessive fibrosis that causes organ dysfunction with
aging and aging-associated diseases, identifying
targets that can antagonize the effect of cytokines and
promote fibroblast removal is of potential clinical
significance in reducing human morbidity from
progressive fibrosis.
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Patient-Friendly Recap
• Aging and its associated diseases can result in
excessive scarring in different organs, thereby
contributing to morbidity and death.
• The level of TGF-β1 –– a protein that
contributes to scarring –– increases in the
setting of inflammation, heart failure and other
disease states.
• Using mouse embryonic cell lines, the authors
studied how three intracellular signaling
pathways activated by TGF-β1 might affect
the cell death pathways responsible for scar
formation.
• They found that the TGF-β1 effect was
mediated by two pathways, making them
potential targets for the development of new
drugs that may help prevent further scarring.
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